HALO vs. ONC: Halozyme Therapeutics vs. BeOne Medicines Stock Comparison
How do Halozyme Therapeutics (HALO) and BeOne Medicines (ONC) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Halozyme Therapeutics (HALO) and BeOne Medicines (ONC) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Halozyme Therapeutics (HALO) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | HALO | ONC |
|---|---|---|
| Name | Halozyme Therapeutics Inc. | BeOne Medicines Ltd. American Depositary Shares |
| Country/Region | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 11.81 billion USD | 46.49 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | March 16, 2004 | February 3, 2016 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | HALO | ONC |
|---|---|---|
| Total Return (1Y) | 50.94% | 30.59% |
| Total Return (3Y, Annualized) | 41.08% | 30.15% |
| Total Return (5Y, Annualized) | 21.68% | 2.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | HALO | ONC |
|---|---|---|
| Volatility (1Y, Annualized) | 41.19% | 35.90% |
| Beta (5Y) | 0.96 | 0.59 |
| Max Drawdown (5Y) | -49.06% | -68.89% |
| Avg. Volume (3M) | 2.29M | 405.29K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | HALO | ONC |
|---|---|---|
| Sharpe Ratio (1Y) | 1.13 | 0.73 |
| Sortino Ratio (1Y) | 1.78 | 1.15 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; BeOne Medicines (ONC) at 18.40% also sits in the top quartile.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Halozyme Therapeutics (HALO) at 26.93% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Halozyme Therapeutics (HALO) at 59.84% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | HALO | ONC |
|---|---|---|
| ROE (TTM) | 216.38% | 18.40% |
| ROA (TTM) | 22.42% | 8.42% |
| Net Margin (TTM) | 26.93% | 13.86% |
| Operating Margin (TTM) | 59.84% | 22.15% |
| Gross Margin (TTM) | 77.74% | 89.39% |
Growth
Revenue Growth
Both Halozyme Therapeutics (HALO) at 37.55% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Halozyme Therapeutics (HALO) reports EPS growth of -25.36%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.
Growth Metrics
| Metric | HALO | ONC |
|---|---|---|
| Revenue Growth (YoY) | 37.55% | 40.23% |
| Revenue Growth (3Y CAGR) | 28.38% | 55.69% |
| EPS Growth (YoY) | -25.36% | -- |
| EPS Growth (3Y CAGR) | 21.14% | -- |
Financial Strength
Current Ratio (MRQ)
Both Halozyme Therapeutics (HALO) at 3.88 and BeOne Medicines (ONC) at 3.55 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: BeOne Medicines (ONC) carries debt-to-equity ratio of 0.35 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | HALO | ONC |
|---|---|---|
| Current Ratio (MRQ) | 3.88 | 3.55 |
| Debt / Equity (MRQ) | -- | 0.35 |
| Net Debt / EBITDA | 1.90 | -2.80 |
Dividends
Dividend Yield (TTM)
Neither Halozyme Therapeutics (HALO) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Halozyme Therapeutics (HALO) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | HALO | ONC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Halozyme Therapeutics (HALO) at 6.55 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile BeOne Medicines (ONC) reports 7.98, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | HALO | ONC |
|---|---|---|
| P/E Ratio (TTM) | 25.91 | 52.17 |
| P/S Ratio (TTM) | 6.55 | 7.04 |
| P/B Ratio (MRQ) | -213.67 | 7.98 |
| Free Cash Flow Yield (TTM) | 3.48% | 2.21% |